DXC016

DXC016 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Hangzhou DAC Biotech for the treatment of various solid tumors. As part of DAC Biotech's oncology pipeline, DXC016 utilizes the company's specialized ADC platform, although the specific antibody target, linker technology, and cytotoxic payload have not yet been publicly disclosed. The therapeutic is intended to provide a targeted approach to cancer treatment by selectively binding to antigens on the surface of tumor cells and releasing its potent chemical payload intracellularly to induce cell death while minimizing systemic toxicity.